1. Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents
   E. V. Shubnikova et al, 2020, Bezopasnost' i risk farmakoterapii CrossRef
2. Hypocalcemia with Immune Checkpoint Inhibitors: The Disparity among Various Reports
   Swarna Sri Nalluru et al, 2020, International Journal of Endocrinology CrossRef
3. Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance
   Anna Passarelli et al, 2020, Front. Immunol. CrossRef
4. Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy
   María Florencia Mercogliano et al, 2021, Cancers CrossRef
5. Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identifies Immune Checkpoint Inhibitor Therapy-Related Pneumonitis
   Carlo Augusto Mallio et al, 2021, Cancers CrossRef
6. Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
   Kellsye P Fabian et al, 2021, J Immunother Cancer CrossRef
7. Drug-Associated Giant Cell Arteritis with Scalp Necrosis After Treatment with Pembrolizumab: a Case Report
   Bassel Bou Dargham et al, 2022, SN Compr. Clin. Med. CrossRef
8. Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis
   Anne Sofie Sørensen et al, 2022, Arthritis Res Ther CrossRef
9. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer.
   Simona Bungau, 0 CrossRef
10. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
    Leticia Alserawan et al, 2022, IJMS CrossRef
11. Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma
    Marta Morante et al, 2022, Biomolecules CrossRef
12. null
    Nabil E. Omar et al, 2022 CrossRef
13. null
    Polaczek Mateusz Marek et al, 2023 CrossRef
14. null
    Marzieh Norouzian et al, 2023 CrossRef
15. Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report
    Anna Passarelli et al, 2023, Front. Immunol. CrossRef